<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?>
<document xmlns:voc="http://www.hl7.org/v3/voc" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="6E4D54F6-EA1C-4C19-B302-399C5FBF9204" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title mediaType="text/x-hl7-title+xml">CAPTOPRIL TABLETS, USP</title>
<effectiveTime value="20060328" />
<setId root="6E4D54F6-EA1C-4C19-B302-399C5FBF9204" />
<versionNumber value="1" />
<author>
  <time/>
  <assignedEntity>
   <representedOrganization>
    <name>DuPont Pharma</name>
   </representedOrganization>
  </assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="9DCD8FA9-07CE-CBD6-FD40-D6A73C4C63F9" />
<effectiveTime value="20060328" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="60951-721" codeSystem="2.16.840.1.113883.6.69" />
<name>Captopril</name>
<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="12.5">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="12.5" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="9G64RSX1XD" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>captopril</name>
<activeMoiety>
<activeMoiety>
<code code="9G64RSX1XD" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>captopril</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>Captopril</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>corn starch</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>microcrystalline cellulose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>lactose monohydrate, spray dried</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>stearic acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="60951-721-70" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"><originalText>WHITE</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"><originalText>ROUND</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="5" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="2" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">Endo;721</value>
</characteristic>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="60951-722" codeSystem="2.16.840.1.113883.6.69" />
<name>Captopril</name>
<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="25">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="25" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="9G64RSX1XD" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>captopril</name>
<activeMoiety>
<activeMoiety>
<code code="9G64RSX1XD" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>captopril</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>Captopril</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>corn starch</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>microcrystalline cellulose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>lactose monohydrate, spray dried</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>stearic acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="60951-722-70" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"><originalText>WHITE</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"><originalText>ROUND</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="7" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="4" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">Endo;722</value>
</characteristic>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="60951-724" codeSystem="2.16.840.1.113883.6.69" />
<name>Captopril</name>
<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="50">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="50" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="9G64RSX1XD" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>captopril</name>
<activeMoiety>
<activeMoiety>
<code code="9G64RSX1XD" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>captopril</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>Captopril</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>corn starch</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>microcrystalline cellulose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>lactose monohydrate, spray dried</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>stearic acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="60951-724-70" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"><originalText>WHITE</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"><originalText>ROUND</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="9" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="2" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">Endo;724</value>
</characteristic>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="60951-727" codeSystem="2.16.840.1.113883.6.69" />
<name>Captopril</name>
<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="100">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="100" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="9G64RSX1XD" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>captopril</name>
<activeMoiety>
<activeMoiety>
<code code="9G64RSX1XD" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>captopril</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>Captopril</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>corn starch</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>microcrystalline cellulose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>lactose monohydrate, spray dried</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>stearic acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="60951-727-70" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"><originalText>WHITE</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"><originalText>ROUND</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="11" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="2" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">Endo;727</value>
</characteristic>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section ID="SEAB29D07-3362-41AE-921D-8EB2B9EDCCD4">
<id root="48132441-C109-1F03-2F6E-E836DAE9F4B4" />
<code code="34066-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="BOXED WARNING" />
<text><paragraph><content styleCode="bold">USE IN PREGNANCY</content><br /><content styleCode="bold">When used in pregnancy during the second and third
                                trimesters, ACE inhibitors can cause injury and even death to the
                                developing fetus. </content>When pregnancy is detected, captopril   should be discontinued as soon as possible. <content styleCode="bold">See <linkHtml href="#S4AEB2500-4739-44CC-97E0-41489BAE28FB">WARNINGS: Fetal/Neonatal Morbidity and
                            Mortality</linkHtml>.</content></paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SD763C5A0-3B88-4834-9A31-61AEFFCACBD4">
<id root="439E55D8-27AB-C9B9-79A4-1FF50F78DA26" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION" />
<title mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text><paragraph>Captopril is a specific competitive inhibitor of angiotensin I&#8211; converting enzyme (ACE), the enzyme responsible for the
                            conversion of angiotensin I to angiotensin II.</paragraph><paragraph>Captopril is designated chemically as
                            1-[(2S)-3-mercapto-2-methylpropionyl]-L-proline; and has the following
                            structural formula:</paragraph><paragraph><renderMultiMedia referencedObject="MM10" /></paragraph><paragraph>Captopril is a white to off-white crystalline powder that may
                            have a slight sulfurous odor; it is soluble in water (approx. 160
                            mg/mL), methanol, and ethanol and sparingly soluble in chloroform and
                            ethyl acetate.</paragraph><paragraph>Each tablet, for oral administration, contains captopril, 12.5
                            mg, 25 mg, 50 mg, or 100 mg and the following inactive ingredients: corn
                            starch; microcrystalline cellulose; lactose monohydrate, spray dried;
                            and stearic acid.</paragraph></text>
<effectiveTime value="20060328" />
<component>
<observationMedia ID="MM10">
<value mediaType="image/jpg" xsi:type="ED"><reference value="captopril-figure-1.jpg" /></value>
</observationMedia>
</component>
</section>
</component>
<component>
<section ID="SD7FF5A75-3571-44C1-80D7-EB32756E35AB">
<id root="5A5CA5AE-509B-64C4-EB4D-0D34F230D0E3" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY" />
<title mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<effectiveTime value="20060328" />
<component>
<section ID="S6336727E-514A-4482-8D7B-156F7C935264">
<id root="E20128D0-AB57-AF66-C6B6-26E42BDE1A3F" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Mechanism of Action</title>
<text><paragraph>The mechanism of action of captopril has not yet been
                                    fully elucidated. Its beneficial effects in hypertension and
                                    heart failure appear to result primarily from suppression of the
                                    renin-angiotensin-aldosterone system. However, there is no
                                    consistent correlation between renin levels and response to the
                                    drug. Renin, an enzyme synthesized by the kidneys, is released
                                    into the circulation where it acts on a plasma globulin
                                    substrate to produce angiotensin I, a relatively inactive
                                    decapeptide. Angiotensin I is then converted by angiotensin
                                    converting enzyme (ACE) to angiotensin II, a potent endogenous
                                    vasoconstrictor substance. Angiotensin II also stimulates
                                    aldosterone secretion from the adrenal cortex, thereby
                                    contributing to sodium and fluid retention.</paragraph><paragraph>Captopril prevents the conversion of angiotensin I to
                                    angiotensin II by inhibition of ACE, a peptidyldipeptide carboxy
                                    hydrolase. This inhibition has been demonstrated in both healthy
                                    human subjects and in animals by showing that the elevation of
                                    blood pressure caused by exogenously administered angiotensin I
                                    was attenuated or abolished by captopril. In animal studies,
                                    captopril did not alter the pressor responses to a number of
                                    other agents, including angiotensin II and norepinephrine,     indicating specificity of action.</paragraph><paragraph>ACE is identical to &#8220;bradykininase&#8221;,
                                    and captopril may also interfere with the degradation of the
                                    vasodepressor peptide, bradykinin. Increased concentrations of
                                    bradykinin or prostaglandin E<sub>2</sub> may also have a role
                                    in the therapeutic effect of captopril.</paragraph><paragraph>Inhibition of ACE results in decreased plasma angiotensin
                                    II and increased plasma renin activity (PRA), the latter
                                    resulting from loss of negative feedback on renin release caused
                                    by reduction in angiotensin II. The reduction of angiotensin II
                                    leads to decreased aldosterone secretion, and, as a result,
                                    small increases in serum potassium may occur along with sodium
                                    and fluid loss.</paragraph><paragraph>The antihypertensive effects persist for a longer period
                                    of time than does demonstrable inhibition of circulating ACE. It
                                    is not known whether the ACE present in vascular endothelium is
                                    inhibited longer than the ACE in circulating blood.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S835FC991-B1FA-48E8-86F6-E030DE5576F7">
<id root="296C8249-C10E-538E-5FEF-7D02D195D0E8" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Pharmacokinetics</title>
<text><paragraph>After oral administration of therapeutic doses of
                                    captopril, rapid absorption occurs with peak blood levels at
                                    about one hour. The presence of food in the gastrointestinal
                                    tract reduces absorption by about 30 to 40 percent; captopril
                                    therefore should be given one hour before meals. Based on
                                    carbon-14 labeling, average minimal absorption is approximately
                                    75 percent. In a 24-hour period, over 95 percent of the absorbed
                                    dose is eliminated in the urine; 40 to 50 percent is unchanged
                                    drug; most of the remainder is the disulfide dimer of captopril
                                    and captopril-cysteine disulfide.</paragraph><paragraph>Approximately 25 to 30 percent of the circulating drug is
                                    bound to plasma proteins. The apparent elimination half-life for
                                    total radioactivity in blood is probably less than three hours.
                                    An accurate determination of half-life of unchanged captopril is
                                    not, at present, possible, but it is probably less than 2 hours.
                                    In patients with renal impairment, however, retention of
                                    captopril occurs (see <linkHtml href="#S8EF4CB1E-A155-4A7C-9341-2F9DD5DE6521">DOSAGE AND                        ADMINISTRATION</linkHtml>).</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S1E4BA488-52C2-43DC-BD1D-62E486BA4B8C">
<id root="2C3DE46B-0ACD-39FB-0C01-130C541CFDE5" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Pharmacodynamics</title>
<text><paragraph>Administration of captopril results in a reduction of                    peripheral arterial resistance in hypertensive patients with
                                    either no change, or an increase, in cardiac output. There is an
                                    increase in renal blood flow following administration of
                                    captopril and glomerular filtration rate is usually unchanged.</paragraph><paragraph>Reductions of blood pressure are usually maximal 60 to 90
                                    minutes after oral administration of an individual dose of
                                    captopril. The duration of effect is dose related. The reduction
                                    in blood pressure may be progressive, so to achieve maximal
                                    therapeutic effects, several weeks of therapy may be required.
                                    The blood pressure lowering effects of captopril and
                                    thiazide-type diuretics are additive. In contrast, captopril and
                                    beta-blockers have a less than additive effect.</paragraph><paragraph>Blood pressure is lowered to about the same extent in
                                    both standing and supine positions. Orthostatic effects and
                                    tachycardia are infrequent but may occur in volume-depleted
                                    patients. Abrupt withdrawal of captopril has not been associated  with a rapid increase in blood pressure.</paragraph><paragraph>In patients with heart failure, significantly decreased
                                    peripheral (systemic vascular) resistance and blood pressure
                                    (afterload), reduced pulmonary capillary wedge pressure
                                    (preload) and pulmonary vascular resistance, increased cardiac
                                    output, and increased exercise tolerance time (ETT) have been            demonstrated. These hemodynamic and clinical effects occur after
                                    the first dose and appear to persist for the duration of
                                    therapy. Placebo controlled studies of 12 weeks duration in
                                    patients who do not respond adequately to diuretics and
                                    digitalis show no tolerance to beneficial effects of ETT; open
                                    studies, with exposure up to 18 months in some cases, also
                                    indicate that ETT benefit is maintained. Clinical improvement
                                    has been observed in some patients where acute hemodynamic
                                    effects were minimal.</paragraph><paragraph>In a multicenter study, a marketed brand of captopril
                                    tablets were well tolerated in the presence of other therapies
                                    such as aspirin, beta blockers, nitrates, vasodilators, calcium
                                    antagonists and diuretics.</paragraph><paragraph>Studies in rats and cats indicate that captopril does not
                                    cross the blood-brain barrier to any significant
                                extent.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
</section>
</component>
<component>
<section ID="S349F907A-A56E-4DCD-9626-5E679CC94A7B">
<id root="8B5C2CA2-4C60-D865-E468-F6EE942753AC" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS &amp; USAGE" />
<title mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<effectiveTime value="20060328" />
<component>
<section ID="S34341F2C-CE86-4DDD-9400-DE1CB7D4AA0B">
<id root="CBEC0857-277C-4099-D904-B36F1DE38497" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Hypertension</title>
<text><paragraph>Captopril tablets are indicated for the treatment of
                                    hypertension.</paragraph><paragraph>In using captopril, consideration should be given to the
                                    risk of neutropenia/agranulocytosis (see <linkHtml href="#S2D1A1BB6-E269-4520-8693-E83DCF365182">WARNINGS</linkHtml>).</paragraph><paragraph>Captopril may be used as initial therapy for patients
                                    with normal renal function, in whom the risk is relatively low.
                                    In patients with impaired renal function, particularly those
                                    with collagen vascular disease, captopril should be reserved for
                                    hypertensives who have either developed unacceptable side
                                    effects on other drugs, or have failed to respond satisfactorily
                                    to drug combinations.</paragraph><paragraph>Captopril is effective alone and in combination with
                                    other antihypertensive agents, especially thiazide-type
                                    diuretics. The blood pressure lowering effects of captopril and
                                    thiazides are approximately additive.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S016D0F23-4D49-426D-B018-3631EF0423A0">
<id root="973C6B50-A80A-1192-BB77-21D9C3151EF5" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Heart Failure</title>
<text><paragraph>Captopril tablets are indicated in the treatment of
                                    congestive heart failure usually in combination with diuretics       and digitalis. The beneficial effect of captopril in heart
                                    failure does not require the presence of digitalis; however,
                                    most controlled clinical trial experience with captopril has
                                    been in patients receiving digitalis, as well as diuretic
                                    treatment.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
</section>
</component>
<component>
<section ID="SECF866CF-70CD-4259-9497-0CD68D5A6CC0">
<id root="2538E284-18E4-9D0C-CDB7-49657693E8AF" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS" />
<title mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text><paragraph>Captopril tablets are contraindicated in patients who are
                            hypersensitive to this product or any other angiotensin-converting
                            enzyme inhibitor (e.g., a patient who has experienced angioedema during
                            therapy with any other ACE inhibitor).</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S2D1A1BB6-E269-4520-8693-E83DCF365182">
<id root="D7012101-4038-2F40-9711-C23F449DDE82" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS" />
<title mediaType="text/x-hl7-title+xml">WARNINGS</title>
<effectiveTime value="20060328" />
<component>
<section ID="S230ECA55-EDA4-4086-81C3-9D71634E8670">
<id root="669C1C89-8208-4E3B-897B-1CA1C25267DD" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Anaphylactoid and Possibly Related Reactions</title>
<text><paragraph>Presumably because angiotensin-converting enzyme
                                    inhibitors affect the metabolism of eicosanoids and
                                    polypeptides, including endogenous bradykinin, patients
                                    receiving ACE inhibitors (including captopril) may be subject to
                                    a variety of adverse reactions, some of them
                                serious.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SD8144654-4C24-4E68-A871-CA25B1B7D459">
<id root="E97829A7-7C43-E8DE-4DBF-BD04F02824DA" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Angioedema</title>
<text><paragraph>Angioedema involving the extremities, face, lips, mucous
                                    membranes, tongue, glottis or larynx has been seen in patients
                                    treated with ACE inhibitors, including captopril. If angioedema
                                    involves the tongue, glottis or larynx, airway obstruction may
                                    occur and be fatal. Emergency therapy, including but not
                                    necessarily limited to, subcutaneous administration of a 1:1000
                                    solution of epinephrine should be promptly instituted. </paragraph><paragraph>Swelling confined to the face, mucous membranes of the
                                    mouth, lips and extremities has usually resolved with
                                    discontinuation of captopril; some cases required medical
                                    therapy. (See&#160;<linkHtml href="#S485025FE-2EE3-40B2-A7C2-7FB761B205E4"> PRECAUTIONS:                   Information for Patients</linkHtml>&#160;and <linkHtml href="#SFAAE546C-E220-4821-8DF7-953AA69126A4"> ADVERSE
                                        REACTIONS</linkHtml>.)</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S9C8C7E3D-FF7F-460A-896F-E3DC9AB4EE58">
<id root="A05E753A-E1D5-B541-2CEC-009302DB93AE" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Anaphylactoid reactions during desensitization</title>
<text><paragraph>Two patients undergoing desensitizing treatment with
                                    hymenoptera venom while receiving ACE inhibitors sustained
                                    life-threatening anaphylactoid reactions. In the same patients,
                                    these reactions were avoided when ACE inhibitors were
                                    temporarily withheld, but they reappeared upon inadvertent
                                    rechallenge.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S16E9CAB3-D8D8-402A-8569-806B2DEBA881">
<id root="028E8D65-6557-BDB8-35D6-E6C7C8169764" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Anaphylactoid reactions during membrane exposure</title>
<text><paragraph>Anaphylactoid reactions have been reported in patients
                                    dialyzed with high-flux membranes and treated concomitantly with
                                    an ACE inhibitor. Anaphylactoid reactions have also been
                                    reported in patients undergoing low-density lipoprotein
                                    apheresis with dextran sulfate absorption (a procedure dependent
                                    upon devices not approved in the United States).</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S6758ED9D-CBB6-4AA7-AD04-AA0640FF71D8">
<id root="7080710C-7C28-7A00-0B05-442E17CC7A6A" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Neutropenia/Agranulocytosis</title>
<text><paragraph>Neutropenia (&lt;1000/mm<sup>3</sup>) with myeloid
                                    hypoplasia has resulted from use of captopril. About half of the
                                    neutropenic patients developed systemic or oral cavity
                                    infections or other features of the syndrome of agranulocytosis.</paragraph><paragraph>The risk of neutropenia is dependent on the clinical
                                    status of the patient:</paragraph><paragraph>In clinical trials in patients with hypertension who have
                                    normal renal function (serum creatinine less than 1.6 mg/dL and
                                    no collagen vascular disease), neutropenia has been seen in one
                                    patient out of over 8,600 exposed.</paragraph><paragraph>In patients with some degree of renal failure (serum
                                    creatinine at least 1.6 mg/dL) but no collagen vascular disease,
                                    the risk of neutropenia in clinical trials was about 1 per 500,
                                    a frequency over 15 times that for uncomplicated hypertension.
                                    Daily doses of captopril were relatively high in these patients,
                                    particularly in view of their diminished renal function. In
                                    foreign marketing experience in patients with renal failure, use
                                    of allopurinol concomitantly with captopril has been associated  with neutropenia but this association has not appeared in U.S.
                                    reports.</paragraph><paragraph>In patients with collagen vascular diseases (e.g.,
                                    systemic lupus erythematosus, scleroderma) and impaired renal
                                    function, neutropenia occurred in 3.7 percent of patients in
                                    clinical trials.</paragraph><paragraph>While none of the over 750 patients in formal clinical
                                    trials of heart failure developed neutropenia, it has occurred
                                    during the subsequent clinical experience. About half of the
                                    reported cases had serum creatinine &#8805;1.6 mg/dL and
                                    more than 75 percent were in patients also receiving
                                    procainamide. In heart failure, it appears that the same risk
                                    factors for neutropenia are present.</paragraph><paragraph>The neutropenia has usually been detected within three
                                    months after captopril was started. Bone marrow examinations in
                                    patients with neutropenia consistently showed myeloid
                                    hypoplasia, frequently accompanied by erythroid hypoplasia and
                                    decreased numbers of megakaryocytes (e.g., hypoplastic bone
                                    marrow and pancytopenia); anemia and thrombocytopenia were
                                    sometimes seen.</paragraph><paragraph>In general, neutrophils returned to normal in about two
                                    weeks after captopril was discontinued, and serious infections
                                    were limited to clinical complex patients. About 13 percent of
                                    the cases of neutropenia have ended fatally, but almost all
                                    fatalities were in patients with serious illness, having
                                    collagen vascular disease, renal failure, heart failure or
                                    immunosuppressant therapy, or a combination of these
                                    complicating factors.</paragraph><paragraph><content styleCode="bold">Evacuation of the hypertensive or
                                        heart failure patient should always include assessment of
                                        renal function.</content></paragraph><paragraph>If captopril is used in patients with impaired renal
                                    function, white blood cell and differential counts should be
                                    evaluated prior to starting treatment and at approximately
                                    two-week intervals for about three months, then periodically. </paragraph><paragraph>In patients with collagen vascular disease or who are
                                    exposed to other drugs known to affect the white cells or immune
                                    response, particularly when there is impaired renal function,
                                    captopril should be used only after assessment of benefit and
                                    risk, and then with caution. </paragraph><paragraph>All patients treated with captopril should be told to
                                    report any signs of infection (e.g., sore throat, fever). If
                                    infection is suspected, white cell counts should be performed
                                    without delay.</paragraph><paragraph>Since discontinuation of captopril and other drugs has
                                    generally led to prompt return of the white count to normal,
                                    upon confirmation of neutropenia (neutrophils count&lt;1000/mm<sup>3</sup>) the physician should withdraw
                                    captopril and closely follow the patient&#8217;s                             course.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S3ED14D86-DE25-40EA-A462-4201A3C1C3B2">
<id root="8DF15AB2-03AF-247B-D8EE-434A055553F7" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Proteinuria</title>
<text><paragraph>Total urinary proteins greater than 1 g per day were seen
                                    in about 0.7 percent of patients receiving captopril. About 90
                                    percent of affected patients had evidence of prior renal disease
                                    or received relatively high doses of captopril (in excess of 150
                                    mg/day), or both. The nephrotic syndrome occurred in about
                                    one-fifth of proteinuric patients. In most cases, proteinuria
                                    subsided or cleared within six months whether or not captopril
                                    was continued. Parameters of renal function, such as BUN and
                                    creatinine, were seldom altered in the patients with
                                    proteinuria.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S75C0FC90-42F3-438F-8101-526AA40EB6C2">
<id root="C840C031-8429-5901-BAC8-DBD250624A06" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Hypotension</title>
<text><paragraph>Excessive hypotension was rarely seen in hypertensive
                                    patients but is a possible consequence of captopril use in                 salt/volume depleted persons (such as those treated vigorously
                                    with diuretics), patients with heart failure or those patients
                                    undergoing renal dialysis. (See <linkHtml href="#S8B1831E5-B0BD-49C5-AF9F-B4F6E1FF7AB6">PRECAUTIONS:
                                        Drug Interactions</linkHtml>.)</paragraph><paragraph>In heart failure, where the blood pressure was either
                                    normal or low, transient decreases in mean blood pressure
                                    greater than 20 percent were recorded in about half of the
                                    patients. This transient hypotension is more likely to occur
                                    after any of the first several doses and is usually well
                                    tolerated, producing either no symptoms or brief mild
                                    lightheadedness, although in rare instances it has been
                                    associated with arrhythmia or conduction defects. Hypotension
                                    was the reason for discontinuation of drug in 3.6 percent of
                                    patients with heart failure.</paragraph><paragraph><content styleCode="bold">BECAUSE OF THE POTENTIAL FALL
                                        IN BLOOD PRESSURE IN THESE PATIENTS, THERAPY SHOULD BE
                                        STARTED UNDER VERY CLOSE MEDICAL SUPERVISION.</content> A
                                    starting dose of 6.25 or 12.5 mg tid may minimize the
                                    hypotensive effect. Patients should be followed closely for the
                                    first two weeks of treatment and whenever the dose of captopril
                                    and/or diuretic is increased. In patients with heart failure,
                                    reducing the dose of diuretic, if feasible, may minimize the
                                    fall in blood pressure.</paragraph><paragraph>Hypotension is not <content styleCode="italics">per
                                    se</content> a reason to discontinue captopril. Some decrease of
                                    systemic blood pressure is a common and desirable observation
                                    upon initiation of captopril treatment in heart failure. The
                                    magnitude of the decrease is greatest early in the course of
                                    treatment; this effect stabilizes within a week or two, and
                                    generally returns to pretreatment levels, without a decrease in
                                    therapeutic efficacy, within two months.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S4AEB2500-4739-44CC-97E0-41489BAE28FB">
<id root="0C009C51-C53F-142B-5CB3-B49BC33B0CEF" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Fetal/Neonatal Morbidity and Mortality</title>
<text><paragraph>ACE inhibitors can cause fetal and neonatal morbidity and
                                    death when administered to pregnant women. Several dozen cases
                                    have been reported in the world literature. When pregnancy is
                                    detected, ACE inhibitors should be discontinued as soon as
                                    possible.</paragraph><paragraph>The use of ACE inhibitors during the second and third
                                    trimesters of pregnancy has been associated with fetal and
                                    neonatal injury, including hypotension, neonatal skull
                                    hypoplasia, anuria, reversible or irreversible renal failure,
                                    and death. Oligohydramnios has also been reported, presumably       resulting from decreased fetal renal function; oligohydramnios
                                    in this setting has been associated with fetal limb
                                    contractures, craniofacial deformation, and hypoplastic lung
                                    development. Prematurity, intrauterine growth retardation, and
                                    patent ductus arteriosus have also been reported, although it is
                                    not clear whether these occurrences were due to the
                                    ACE-inhibitor exposure.</paragraph><paragraph>These adverse effects do not appear to have resulted from
                                    intrauterine ACE-inhibitor exposure that has been limited to the
                                    first trimester. Mothers whose embryos and fetuses are exposed
                                    to ACE inhibitors only during the first trimester should be so
                                    informed. Nonetheless, when patients become pregnant, physicians
                                    should make every effort to discontinue the use of captopril as
                                    soon as possible.</paragraph><paragraph>Rarely (probably less often than once in every thousand
                                    pregnancies), no alternative to ACE inhibitors will be found. In
                                    these rare cases, the mothers should be apprised of the
                                    potential hazards to their fetuses, and serial ultrasound
                                    examinations should be performed to assess the intraamniotic
                                    environment.</paragraph><paragraph>If oligohydramnios is observed, captopril should be
                                    discontinued unless it is considered life-saving for the mother.                   Contraction stress testing (CST), a non-stress test (NST), or                     biophysical profiling (BPP) may be appropriate, depending upon
                                    the week of pregnancy. Patients and physicians should be aware,
                                    however, that oligohydramnios may not appear until after the
                                    fetus has sustained irreversible injury.</paragraph><paragraph>Infants with histories of <content styleCode="italics">in
                                        utero</content> exposure to ACE inhibitors should be closely
                                    observed for hypotension, oliguria, and hyperkalemia. If
                                    oliguria occurs, attention should be directed toward support of
                                    blood pressure and renal perfusion. Exchange transfusion or
                                    dialysis may be required as a means of reversing hypotension
                                    and/or substituting for disordered renal function. While
                                    captopril may be removed from the adult circulation by
                                    hemodialysis, there is inadequate data concerning the
                                    effectiveness of hemodialysis for removing it from the
                                    circulation of neonates or children. Peritoneal dialysis is not
                                    effective for removing captopril; there is no information
                                    concerning exchange transfusion for removing captopril from the
                                    general circulation.</paragraph><paragraph>When captopril was given to rabbits at doses about 0.8 to
                                    70 times (on a mg/kg basis) the maximum recommended human dose,
                                    low incidences of craniofacial malformations were seen. No                  teratogenic effects of captopril were seen in studies of
                                    pregnant rats and hamsters. On a mg/kg basis, the doses used
                                    were up to 150 times (in hamsters) and 625 times (in rats) the
                                    maximum recommended human dose.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SD8509228-D2C9-42D3-A5E4-F60B5FFB94DD">
<id root="70B2F07B-DE12-4404-ED3B-3DA44D251354" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Hepatic Failure</title>
<text><paragraph>Rarely, ACE inhibitors have been associated with a
                                    syndrome that starts with cholestatic jaundice and progresses to
                                    fulminant hepatic necrosis and (sometimes) death. The mechanism
                                    of this syndrome is not understood. Patients receiving ACE
                                    inhibitors who develop jaundice or marked elevations of hepatic
                                    enzymes should discontinue the ACE inhibitor and receive
                                    appropriate medical follow-up.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
</section>
</component>
<component>
<section ID="S34F82D8A-47E8-4920-A099-351FD508FC84">
<id root="CD1B3D4B-485F-D673-AB78-8617D2529263" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PRECAUTIONS" />
<title mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
<effectiveTime value="20060328" />
<component>
<section ID="S1EFBEE8A-1FC0-469C-9478-21A3A927DFE9">
<id root="C2D03961-BAB5-91E9-BA69-D0B324B748F3" />
<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GENERAL PRECAUTIONS" />
<title mediaType="text/x-hl7-title+xml">General</title>
<effectiveTime value="20060328" />
<component>
<section ID="P70A18E97-5225-4723-B4ED-91EF593A49BE">
<id root="B3A84D7D-9859-BE45-08DD-5871ADC30346" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Impaired Renal Function</title>
<effectiveTime value="20060328" />
<component>
<section ID="S79D17E94-5225-4723-B4EE-91EF593A49BE">
<id root="4F139467-0AF3-1CB0-3004-E7CA6D7AC45A" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Hypertension &#8211;</title>
<text><paragraph>Some patients with renal disease, particularly
                                            those with severe renal artery stenosis, have developed
                                            increases in BUN and serum creatinine after reduction of
                                            blood pressure with captopril. Captopril dosage
                                            reduction and/or discontinuation of diuretic may be
                                            required. For some of these patients, it may not be
                                            possible to normalize blood pressure and maintain
                                            adequate renal perfusion.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S377B3BBB-5AEA-45EA-857C-4CEE281DC5B9">
<id root="D3F5E20E-D0A0-F66E-BD0B-D8060FE0A0FF" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Heart Failure &#8211;</title>
<text><paragraph>About 20 percent of patients develop stable
                                            elevations of BUN and serum creatinine greater than 20
                                            percent above normal or baseline upon long-term
                                            treatment with captopril. Less than 5 percent of                    patients, generally those with severe preexisting renal
                                            disease, required discontinuation of treatment due to
                                            progressively increasing creatinine; subsequent
                                            improvement probably depends upon the severity of the
                                            underlying renal disease.</paragraph><paragraph>(See <linkHtml href="#SD7FF5A75-3571-44C1-80D7-EB32756E35AB">
                                                CLINICAL PHARMACOLOGY</linkHtml>, <linkHtml href="#S8EF4CB1E-A155-4A7C-9341-2F9DD5DE6521">
                                                DOSAGE AND ADMINISTRATION</linkHtml>, <linkHtml href="#S01AF1A12-BFA5-483E-8218-065A1AAF8AD5">
                                                ADVERSE REACTIONS: Altered Laboratory
                                            Findings</linkHtml>).</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
</section>
</component>
<component>
<section ID="S9DA6258E-BFF8-4D3C-BD9F-9EF5D61DE9FC">
<id root="15FF89C3-541C-0D8E-24B2-D3A21399845C" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Hyperkalemia</title>
<text><paragraph>Elevations in serum potassium have been observed
                                            in some patients treated with ACE inhibitors, including
                                            captopril. When treated with ACE inhibitors, patients at
                                            risk for the development of hyperkalemia include those
                                            with: renal insufficiency; diabetes mellitus; and those                                     using concomitant potassium-sparing diuretics, potassium
                                            supplements or potassium-containing salt substitutes; or
                                            other drugs associated with increases in serum
                                            potassium. (See <linkHtml href="#S485025FE-2EE3-40B2-A7C2-7FB761B205E4">
                                                PRECAUTIONS: Information for Patients</linkHtml> and<linkHtml href="#S8B1831E5-B0BD-49C5-AF9F-B4F6E1FF7AB6"> Drug
                                                Interactions</linkHtml>; <linkHtml href="#S01AF1A12-BFA5-483E-8218-065A1AAF8AD5">
                                                ADVERSE REACTIONS: Altered Laboratory
                                            Findings</linkHtml>.)</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SA6F39D7C-271B-41D9-A8A0-06088539C844">
<id root="5F92B5A1-E744-BC87-D537-8DAFE5CCA9FB" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Cough</title>
<text><paragraph>Presumably due to the inhibition of the
                                            degradation of endogenous bradykinin, persistent
                                            nonproductive cough has been reported with all ACE
                                            inhibitors, always resolving after discontinuation of
                                            therapy. ACE inhibitor-induced cough should be
                                            considered in the differential diagnosis of
                                        cough.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S3823EAAE-0974-41CF-BC96-B7ACCF1688B3">
<id root="36D5E2FA-E162-EF99-A551-295D467CA0F4" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Valvular Stenosis</title>
<text><paragraph>There is concern, on theoretical grounds, that
                                            patients with aortic stenosis might be at particular
                                            risk of decreased coronary perfusion when treated with
                                            vasodilators because they do not develop as much
                                            afterload reduction as others.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S94614CB9-20D4-4BE7-A1CB-03AF7501BDF1">
<id root="527D3B7A-A79A-8B0B-6793-C20A8C33C5C9" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Surgery/Anesthesia</title>
<text><paragraph>In patients undergoing major surgery or during
                                            anesthesia with agents that produce hypotension,
                                            captopril will block angiotensin II formation secondary
                                            to compensatory renin release. If hypotension occurs and
                                            is considered to be due to this mechanism, it can be
                                            corrected by volume exposure.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
</section>
</component>
<component>
<section ID="S50F24D2D-3F9A-4C5C-8CD7-7EF4298E2514">
<id root="49B48B2F-DAC7-3758-5314-4E7C3126D70C" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Hemodialysis</title>
<text><paragraph>Recent clinical observations have shown an
                                            association of hypersensitivity-like (anaphylactoid)
                                            reactions during hemodialysis with high-flux dialysis  membranes (e.g., AN69) in patients receiving ACE
                                            inhibitors. In these patients, consideration should be
                                            given to using a different type of dialysis membrane or
                                            a different class of medication. (See <linkHtml href="#S16E9CAB3-D8D8-402A-8569-806B2DEBA881">
                                                WARNINGS: Anaphylactoid reactions during membrane
                                                exposure</linkHtml>.)</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S485025FE-2EE3-40B2-A7C2-7FB761B205E4">
<id root="5B199E0A-3EB7-DBFE-55F1-BC4D5B1DCBB8" />
<code code="34076-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Information for Patients" />
<title mediaType="text/x-hl7-title+xml">Information for Patients</title>
<text><paragraph>Patients should be advised to immediately report to their
                                    physician any signs or symptoms suggesting angioedema (e.g.,
                                    swelling of face, eyes, lips, tongue, larynx and extremities;
                                    difficulty in swallowing or breathing; hoarseness) and to
                                    discontinue therapy. (See <linkHtml href="#SD8144654-4C24-4E68-A871-CA25B1B7D459"> WARNINGS:
                                        Angioedema</linkHtml>.)</paragraph><paragraph>Patients should be told to report promptly any indication
                                    of infection (e.g., sore throat, fever), which may be a sign of
                                    neutropenia, or of progressive edema which might be related to
                                    proteinuria and nephrotic syndrome.</paragraph><paragraph>All patients should be cautioned that excessive
                                    perspiration and dehydration may lead to an excessive fall in
                                    blood pressure because of reduction in fluid volume. Other
                                    causes of volume depletion such as vomiting or diarrhea may also
                                    lead to a fall in blood pressure; patients should be advised to
                                    consult with the physician.</paragraph><paragraph>Patients should be advised not to use potassium-sparing
                                    diuretics, potassium supplements or potassium-containing salt
                                    substitutes without consulting their physician.
                                        (See&#160;<linkHtml href="#S1EFBEE8A-1FC0-469C-9478-21A3A927DFE9"> PRECAUTIONS:
                                        General</linkHtml> and <linkHtml href="#S8B1831E5-B0BD-49C5-AF9F-B4F6E1FF7AB6"> Drug
                                        Interactions</linkHtml>; <linkHtml href="#SFAAE546C-E220-4821-8DF7-953AA69126A4"> ADVERSE
                                        REACTIONS: Captopril</linkHtml>.)</paragraph><paragraph>Patients should be warned against interruption or
                                    discontinuation of medication unless instructed by the
                                    physician.</paragraph><paragraph>Heart failure patients on captopril therapy should be
                                    cautioned against rapid increases in physical activity.</paragraph><paragraph>Patients should be informed that captopril should be
                                    taken one hour before meals (see <linkHtml href="#S8EF4CB1E-A155-4A7C-9341-2F9DD5DE6521"> DOSAGE AND
                                        ADMINISTRATION</linkHtml>).</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S2B07955C-67D5-4B9F-8CCE-64D510D7341D">
<id root="E0C14132-796E-4C55-3864-F0C796DBEC77" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Pregnancy" />
<title mediaType="text/x-hl7-title+xml">Pregnancy</title>
<text><paragraph>Female patients of childbearing age should be told about
                                    the consequences of second- and third-trimester exposure to ACE
                                    inhibitors, and they should also be told that these consequences
                                    do not appear to have resulted from intrauterine ACE-inhibitor
                                    exposure that has been limited to the first trimester. These
                                    patients should be asked to report pregnancies to their
                                    physicians as soon as possible.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S8B1831E5-B0BD-49C5-AF9F-B4F6E1FF7AB6">
<id root="A75094B9-9A5B-D9E3-0A2C-19B33E8F821A" />
<code code="34073-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Drug Interactions" />
<title mediaType="text/x-hl7-title+xml">Drug Interactions</title>
<effectiveTime value="20060328" />
<component>
<section ID="S46C444F1-4795-46B6-8F72-2D0269D58295">
<id root="82F0D4C2-9CCB-3F41-8734-60B0B3ACEB87" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Hypotension &#8211; Patients on Diuretic Therapy</title>
<text><paragraph>Patients on diuretics and especially those in
                                            whom diuretic therapy was recently instituted, as well
                                            as those on severe dietary salt restriction or dialysis,
                                            may occasionally experience a precipitous reduction of
                                            blood pressure usually within the first hour after
                                            receiving the initial dose of captopril.</paragraph><paragraph>The possibility of hypotensive effects with                            captopril can be minimized by either discontinuing the
                                            diuretic or increasing the salt intake approximately one
                                            week prior to initiation of treatment with captopril or
                                            initiating therapy with small doses (6.25 or 12.5 mg).
                                            Alternatively, provide medical supervision for at least
                                            one hour after the initial dose. If hypotension occurs,
                                            the patient should be placed in a supine position and,
                                            if necessary, receive an intravenous infusion of normal
                                            saline. This transient hypotensive response is not a
                                            contraindication to further doses which can be given
                                            without difficulty once the blood pressure has increased
                                            after volume expansion.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S19C88F11-B440-4E6C-99C0-B762A92C7515">
<id root="10E0C5D8-19F5-CCA0-4279-C0C375A2F7D5" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Agents Having Vasodilator Activity</title>
<text><paragraph>Data on the effect of concomitant use of other
                                            vasodilators in patients receiving captopril for heart
                                            failure are not available; therefore, nitroglycerin or
                                            other nitrates (as used for management of angina) or
                                            other drugs having vasodilator activity should, if  possible, be discontinued before starting captopril. If
                                            resumed during captopril therapy, such agents should be
                                            administered cautiously, and perhaps at lower
                                        dosage.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S86C0FBA1-15A0-4B78-BF1F-B9934B432C6C">
<id root="883BFD5F-9C66-7AC9-43ED-C67AE3BD9A9F" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Agents Causing Renin Release</title>
<text><paragraph>Captopril&#8217;s effect will be augmented by
                                            antihypertensive agents that cause renin release. For
                                            example, diuretics (e.g., thiazides) may activate the
                                            renin-angiotensin-aldosterone system.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SF95AC4E0-485A-4350-AC6B-7C72DBC04E9B">
<id root="7A11E156-E0C4-5EE5-51FB-1020D99C0EFD" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Agents Affecting Sympathetic Activity</title>
<text><paragraph>The sympathetic nervous system may be especially       important in supporting blood pressure in patients
                                            receiving captopril alone or with diuretics. Therefore,
                                            agents affecting sympathetic activity (e.g., ganglionic
                                            blocking agents or adrenergic neuron blocking agents)
                                            should be used with caution. Beta-adrenergic blocking drugs add some further antihypertensive effect to
                                            captopril, but the overall response is less than
                                            additive.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S26290912-FDD0-4F06-89A7-46F4123EF431">
<id root="27BCEA53-7902-5C52-1668-1297AB728167" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Agents Increasing Serum Potassium</title>
<text><paragraph>Since captopril decreases aldosterone production,
                                            elevation of serum potassium may occur.
                                            Potassium-sparing diuretics such as spironolactone,
                                            triamterene, or amiloride, or potassium supplements,
                                            should be given only for documented hypokalemia, and
                                            then with caution, since they may lead to a significant
                                            increase of serum potassium. Salt substitutes containing
                                            potassium should also be used with caution.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S96092A96-8505-4771-BFBB-A6645F354FDA">
<id root="23EC4B3C-B203-41D3-7341-A890B3C95702" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Inhibitors Of Endogenous Prostaglandin Synthesis</title>
<text><paragraph>It has been reported that indomethacin may reduce
                                            the antihypertensive effect of captopril, especially in
                                            cases of low renin hypertension. Other nonsteroidal              anti-inflammatory agents (e.g., aspirin) may also have
                                            this effect.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S89036E38-648B-43D5-B42F-08381B0C6A37">
<id root="725D4D22-E74A-F00F-2386-326B1A92789E" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Lithium</title>
<text><paragraph>Increased serum lithium levels and symptoms of
                                            lithium toxicity have been reported in patients
                                            receiving concomitant lithium and ACE inhibitor therapy.
                                            These drugs should be coadministered with caution and
                                            frequent monitoring of serum lithium levels is
                                            recommended. If a diuretic is also used, it may increase
                                            the risk of lithium toxicity.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
</section>
</component>
<component>
<section ID="S61E454DB-D47A-4CA4-8D93-6DBB2F9DE3F2">
<id root="191061AF-8743-B0B8-63D2-E8AED7620CCD" />
<code code="34074-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DRUG &amp;OR LABORATORY TEST                                 INTERACTIONS" />
<title mediaType="text/x-hl7-title+xml">Drug/Laboratory Test Interactions</title>
<text><paragraph>Captopril may cause a false-positive urine test for
                                    acetone.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SBADFA5F0-FD94-4CE6-8DBD-0BB2CFA12D86">
<id root="E80CD590-60A9-C533-E4F7-119F048D3121" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CARCINOGENESIS &amp;                                 MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY" />
<title mediaType="text/x-hl7-title+xml">Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
<text><paragraph>Two-year studies with doses of 50 to 1350 mg/kg/day in
                                    mice and rats failed to show any evidence of carcinogenic
                                    potential. The high dose in these studies is 150 times the
                                    maximum recommended human dose of 450 mg, assuming a 50-kg
                                    subject. On a body-surface-area basis, the high doses for mice
                                    and rats are 13 and 26 times the maximum recommended human dose,
                                    respectively.</paragraph><paragraph>Studies in rats have revealed no impairment of
                                fertility.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SE547BF94-D724-4C2C-B484-E5004666FE7D">
<id root="D4B5E167-7FB6-3DE7-A9A4-0E9792980CBC" />
<code code="34091-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ANIMAL PHARMACOLOGY                                         &amp;OR TOXICOLOGY" />
<title mediaType="text/x-hl7-title+xml">Animal Toxicology</title>
<text><paragraph>Chronic oral toxicity studies were conducted in
                                            rats (2 years), dogs (47 weeks; 1 year), mice (2 years),
                                            and monkeys (1 year). Significant drug-related toxicity
                                            included effects on hematopoiesis, renal toxicity,
                                            erosion/ulceration of the stomach, and variation of
                                            retinal blood vessels.</paragraph><paragraph>Reductions in hemoglobin and/or hematocrit values
                                            were seen in mice, rats, and monkeys at doses 50 to 150                    times the maximum recommended human dose (MRHD),
                                            assuming a 50-kg subject. On a body-surface-area basis,
                                            these doses are 5 to 25 times maximum recommended dose
                                            (MRHD). Anemia, leukopenia, thrombocytopenia, and bone
                                            marrow suppression occurred in dogs at doses 8 to 30
                                            times MRHD on a body-weight basis (4 to 15 times MRHD on
                                            a surface-area basis). The reductions in hemoglobin and
                                            hematocrit values in rats and mice were only significant
                                            at 1 year and returned to normal with continued dosing
                                            by the end of the study. Marked anemia was seen at all
                                            dose levels (8 to 30 times MRHD) in dogs, whereas
                                            moderate to marked leukopenia was noted only at 15 and
                                            30 times MRHD and thrombocytopenia at 30 times MRHD. The
                                            anemia could be reversed upon discontinuation of dosing.              Bone marrow suppression occurred to a varying degree,
                                            being associated only with dogs that died or were
                                            sacrificed in a moribund condition in the 1 year study.
                                            However, in the 47-week study at a dose 30 times MRHD,
                                            bone marrow suppression was found to be reversible upon
                                            continued drug administration.</paragraph><paragraph>Captopril caused hyperplasia of the
                                            juxtaglomerular apparatus of the kidneys in mice and
                                            rats at doses 7 to 200 times MRDH on a body-weight basis
                                            (0.6 to 35 times MRHD on a surface-area basis); in
                                            monkeys at 20 to 60 times MRHD on a body-weight basis (7
                                            to 20 times MRHD on a surface-area basis); and in dogs
                                            at 30 times MRHD on a body-weight basis (15 times MRHD
                                            on a surface-area basis).</paragraph><paragraph>Gastric erosions/ulcerations were increased in
                                            incidence in male rats at 20 to 200 times MRHD on a
                                            body-weight basis (3.5 and 35 times MRHD on a
                                            surface-area basis); in dogs at 30 times MRHD on a
                                            body-weight basis (15 times MRHD on a surface-area
                                            basis); and in monkeys at 65 times MRHD on a body-weight
                                            basis (20 times MRHD on a surface-area basis). Rabbits
                                            developed gastric and intestinal ulcers when given oral                 doses approximately 30 times MRHD on a body-weight basis
                                            (10 times MRHD on a surface-area basis) for only 5 to 7
                                            days.</paragraph><paragraph>In the two-year rat study, irreversible and
                                            progressive variations in the caliber of retinal vessels
                                            (focal sacculations and constrictions) occurred at all
                                            dose levels (7 to 200 times MRHD) on a body-weight
                                            basis; 1 to 35 times MRHD on a surface-area basis in
                                            dose-related fashion. The effect was first observed in
                                            the 88<sup>th </sup>week of dosing, with a progressively
                                            increased incidence thereafter, even after cessation of
                                            dosing.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SA95D1CA3-27EC-496F-ACBE-7C30467A6CED">
<id root="8B6BC0C8-79FA-08AA-2E9C-9D4FA8E931F7" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PREGNANCY" />
<title mediaType="text/x-hl7-title+xml">Pregnancy Categories C (first trimester) and D (second and third
                                trimesters)</title>
<text><paragraph><content styleCode="bold">See <linkHtml href="#S4AEB2500-4739-44CC-97E0-41489BAE28FB">WARNINGS:
                                            Fetal/Neonatal Morbidity and
                                    Mortality</linkHtml>.</content></paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SC5A653B8-9E12-40BC-A132-45EEC3994D4D">
<id root="56CADC7E-FAAE-CA00-936C-9B3983389352" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Nursing Mothers" />
<title mediaType="text/x-hl7-title+xml">Nursing Mothers</title>
<text><paragraph>Concentrations of captopril in human milk are
                                    approximately one percent of those in maternal blood. Because of
                                    the potential for serious adverse reactions in nursing infants
                                    from captopril, a decision should be made whether to discontinue
                                    nursing or to discontinue the drug, taking into account the
                                    importance of captopril to the mother. (See <linkHtml href="#S291592AF-88B3-45F1-873D-B3B095104D39">PRECAUTIONS:
                                        Pediatric Use</linkHtml>.)</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S291592AF-88B3-45F1-873D-B3B095104D39">
<id root="D0FE3F89-A8D6-6051-C1E6-A650DE9428D0" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Pediatric Use" />
<title mediaType="text/x-hl7-title+xml">Pediatric Use</title>
<text><paragraph>Safety and effectiveness in children have not been
                                    established. There is limited experience reported in the
                                    literature with the use of captopril in the pediatric
                                    population; dosage, on a weight basis, was generally reported to
                                    be comparable to or less than that used in adults.</paragraph><paragraph>Infants, especially newborns, may be more susceptible to
                                    the adverse hemodynamic effects of captopril. Excessive,
                                    prolonged and unpredictable decreases in blood pressure and
                                    associated complications, including oliguria and seizures, have
                                    been reported.</paragraph><paragraph>Captopril should be used in children only if other
                                    measures for controlling blood pressure have not been
                                effective.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
</section>
</component>
<component>
<section ID="SFAAE546C-E220-4821-8DF7-953AA69126A4">
<id root="5C83F7AD-718D-FD15-5A74-2DA4783FEF73" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS" />
<title mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<text><paragraph>Reported incidences are based on clinical trials involving
                            approximately 7000 patients.</paragraph></text>
<effectiveTime value="20060328" />
<component>
<section ID="S8B29A1C9-8F67-4E00-AEBC-4F559EAF992C">
<id root="4576EDC0-06F9-40AD-B65F-2613CE4F5D7B" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Renal</title>
<text><paragraph>About one of 100 patients developed proteinuria (see<linkHtml href="#S2D1A1BB6-E269-4520-8693-E83DCF365182">WARNINGS</linkHtml>).</paragraph><paragraph>Each of the following has been reported in approximately
                                    1 to 2 of 1000 patients and are of uncertain relationship to
                                    drug use: renal insufficiency, renal failure, nephrotic
                                    syndrome, polyuria, oliguria, and urinary frequency.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S39F78DB5-A227-4A74-ADE8-AEDE075231EA">
<id root="897210F8-EA44-AC4A-8AB6-407A243B8669" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Hematologic</title>
<text><paragraph>Neutropenia/agranulocytosis has occurred (see <linkHtml href="#S2D1A1BB6-E269-4520-8693-E83DCF365182">WARNINGS</linkHtml>). Cases of anemia, thrombocytopenia, and
                                    pancytopenia have been reported.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S3AE82F8E-B56B-4D0F-B1E6-9036D905AFAE">
<id root="09DC811A-EE2C-A632-F60C-79DC8F087175" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Dermatologic</title>
<text><paragraph>Rash, often with pruritus, and sometimes with fever,
                                    arthralgia, and eosinophilia, occurred in about 4 to 7                        (depending on renal status and dose) of 100 patients, usually
                                    during the first four weeks of therapy. It is usually
                                    maculopapular, and rarely urticarial. The rash is usually mild
                                    and disappears within a few days of dosage reduction, short-term
                                    treatment with an antihistaminic agent, and/or discontinuing
                                    therapy; remission may occur even if captopril is continued.
                                    Pruritus, without rash, occurs in about 2 of 100 patients.
                                    Between 7 and 10 percent of patients with skin rash have shown
                                    eosinophilia and/or positive ANA titers. A reversible associated
                                    pemphigoid-like lesion, and photosensitivity, have also been
                                    reported.</paragraph><paragraph>Flushing or pallor has been reported in 2 to 5 of 1000
                                    patients.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SE4FA77E5-4468-4B6B-960C-6BFA6763861D">
<id root="C4843F3E-11DE-5303-5E20-7965A33AA6B9" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Cardiovascular</title>
<text><paragraph>Hypotension may occur; see <linkHtml href="#S2D1A1BB6-E269-4520-8693-E83DCF365182">WARNINGS</linkHtml> and&#160;<linkHtml href="#S8B1831E5-B0BD-49C5-AF9F-B4F6E1FF7AB6">PRECAUTIONS
                                        (Drug Interactions)</linkHtml> for discussion of hypotension
                                    with captopril therapy.</paragraph><paragraph>Tachycardia, chest pain, and palpitations have each been
                                    observed in approximately 1 of 100 patients.</paragraph><paragraph>Angina pectoris, myocardial infarction,
                                    Raynaud&#8217;s syndrome, and congestive heart failure have
                                    each occurred in 2 to 3 of 1000 patients.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SA03E9965-A7BA-429F-B1FF-B77596706ECC">
<id root="BE68ADAB-5B48-7228-FF0E-E18BE34B6339" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Dysgeusia</title>
<text><paragraph>Approximately 2 to 4 (depending on renal status and dose)
                                    of 100 patients developed a diminution or loss of taste
                                    perception. Taste impairment is reversible and usually
                                    self-limited (2 to 3 months) even with continued drug
                                    administration. Weight loss may be associated with the loss of                                 taste.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S3854D7FE-728B-46F9-93C0-2C2BF74B35A2">
<id root="FC3B3AE6-8BFC-35BC-7AEB-FD539D71F7BE" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Angioedema</title>
<text><paragraph>Angioedema involving the extremities, face, lips, mucous
                                    membranes, tongue, glottis or larynx has been reported in
                                    approximately one in 1000 patients. Angioedema involving the
                                    upper airways has caused fatal airway obstruction.
                                        (See&#160;<linkHtml href="#SD8144654-4C24-4E68-A871-CA25B1B7D459">WARNINGS:
                                        Angioedema</linkHtml> and <linkHtml href="#S485025FE-2EE3-40B2-A7C2-7FB761B205E4">PRECAUTIONS:
                                        Information for Patients</linkHtml>).</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S4FA55A6A-E6C9-441F-9393-CE30A54AFB6B">
<id root="2EFDF34A-1F6C-39BE-14AE-73844788BE26" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Cough</title>
<text><paragraph>Cough has been reported in 0.5 to 2% of patients
                                    treated with captopril in clinical trials (see <linkHtml href="#SA6F39D7C-271B-41D9-A8A0-06088539C844">PRECAUTIONS:
                                        General, Cough</linkHtml>).</paragraph><paragraph>The following have been reported in about 0.5 to 2
                                    percent of patients but did not appear at increased frequency
                                    compared to placebo or other treatments used in controlled
                                    trials: gastric irritation, abdominal pain, nausea, vomiting,
                                    diarrhea, anorexia, constipation, aphthous ulcers, peptic ulcer,
                                    dizziness, headache, malaise, fatigue, insomnia, dry mouth,
                                    dyspnea, alopecia, paresthesias.</paragraph><paragraph>Other clinical adverse effects reported since the drug
                                    was marketed are listed below by body system. In this setting,
                                    an incidence or causal relationship cannot be accurately
                                    determined.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S16E9F7E7-4551-48CE-AB28-383D5CB47018">
<id root="D7E988FF-4563-83AA-C0DD-DC515CF3A200" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Body as a whole</title>
<text><paragraph>Anaphylactoid reactions (see&#160;<linkHtml href="#S230ECA55-EDA4-4086-81C3-9D71634E8670">WARNINGS:
                                        Anaphylactoid and possibly related reactions</linkHtml> and<linkHtml href="#S50F24D2D-3F9A-4C5C-8CD7-7EF4298E2514">PRECAUTIONS: Hemodialysis</linkHtml>).</paragraph><paragraph><content styleCode="bold">General</content><br />Asthenia,
                                    gynecomastia.</paragraph><paragraph><content styleCode="bold">Cardiovascular</content><br />Cardiac
                                    arrest, cerebrovascular accident/insufficiency, rhythm
                                    disturbances, orthostatic hypotension, syncope.</paragraph><paragraph><content styleCode="bold">Dermatologic</content><br />Bullous            pemphigus, erythema multiforme (including Stevens-Johnson
                                    syndrome), exfoliative dermatitis.</paragraph><paragraph><content styleCode="bold">Gastrointestinal</content><br />Pancreatitis, glossitis,
                                    dyspepsia.</paragraph><paragraph><content styleCode="bold">Hematologic</content><br />Anemia,
                                    including aplastic and hemolytic.</paragraph><paragraph><content styleCode="bold">Hepatobilliary</content><br />Jaundice,
                                    hepatitis, including rare cases of necrosis, cholestasis.</paragraph><paragraph><content styleCode="bold">Metabolic</content><br />Symptomatic
                                    hyponatremia.</paragraph><paragraph><content styleCode="bold">Musculoskeletal</content><br />Myalgia,
                                    myasthenia.</paragraph><paragraph><content styleCode="bold">Nervous/Psychiatric</content><br />Ataxia, confusion,
                                    depression, nervousness, somnolence.</paragraph><paragraph><content styleCode="bold">Respiratory</content><br />Bronchospasm, eosinophilic
                                    pneumonitis, rhinitis.</paragraph><paragraph><content styleCode="bold">Special Senses</content><br />Blurred
                                    vision.</paragraph><paragraph><content styleCode="bold">Urogenital</content><br />Impotence.</paragraph><paragraph>As with other ACE inhibitors, a syndrome has been
                                    reported which may include: fever, myalgia, arthralgia,
                                    interstitial nephritis, vasculitis, rash or other dermatologic
                                    manifestations, eosinophilia and an elevated ESR.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S565277C7-6AD5-47D8-82ED-826B14BF0D75">
<id root="58ABDB77-7E00-B64A-4627-1E925D8AFF7F" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Fetal/Neonatal Morbidity and Mortality</title>
<text><paragraph><content styleCode="bold">See <linkHtml href="#S4AEB2500-4739-44CC-97E0-41489BAE28FB">WARNINGS:
                                            Fetal/Neonatal Morbidity and
                                    Mortality</linkHtml>.</content></paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S01AF1A12-BFA5-483E-8218-065A1AAF8AD5">
<id root="1776B0E3-9554-FA18-12C9-4E7822B4CF6D" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Altered Laboratory Findings</title>
<effectiveTime value="20060328" />
<component>
<section ID="SE78DF4C6-915F-48BC-AB6E-CF1E61AF9FDB">
<id root="1E93BC4F-E2FC-414C-4D03-A8AAEB9829C3" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Serum Electrolytes: Hyperkalemia</title>
<text><paragraph>Small increases in serum potassium, especially in
                                            patients with renal impairment (see <linkHtml href="#S34F82D8A-47E8-4920-A099-351FD508FC84">PRECAUTIONS</linkHtml>).</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SCBAFD144-B981-4A26-96B2-3BB3CCD63D7A">
<id root="DAE88834-2831-0BCA-2E07-4C1AC12E3CF7" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Hyponatremia</title>
<text><paragraph>Particularly in patients receiving a low sodium
                                            diet or concomitant diuretics.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S67CDB94B-CFB1-48D9-9545-BA07D190A25C">
<id root="A57EBEEA-F080-9087-E25C-2B82126A247D" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">BUN/Serum Creatinine</title>
<text><paragraph>Transient elevations of BUN or serum creatinine
                                            especially in volume or salt depleted patients or those
                                            with renovascular hypertension may occur. Rapid
                                            reduction of longstanding or markedly elevated blood
                                            pressure can result in decreases in the glomerular
                                            filtration rate and, in turn, lead to increases in BUN
                                            or serum creatinine.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SBA1186C1-05BA-4104-AA91-CBC327DCC73B">
<id root="8270E1FA-E7B0-7472-255C-6B4B155FA8A6" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Hematologic</title>
<text><paragraph>A positive ANA has been reported.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SE7E60826-60E8-4BFA-8918-F1CED7405FF4">
<id root="6AE010D9-D413-F023-D26E-74B2AA5A390C" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Liver Function Tests</title>
<text><paragraph>Elevations of liver transaminases, alkaline
                                            phosphatase, and serum bilirubin have
                                        occurred.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section ID="S37B1F60C-2728-40B1-BF0A-EF5365ADD105">
<id root="DCC63C1F-2F8A-D96F-1617-98CC7BD4E81D" />
<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="OVERDOSAGE" />
<title mediaType="text/x-hl7-title+xml">OVERDOSAGE</title>
<text><paragraph>Correction of hypotension would be of primary concern. Volume
                            expansion with an intravenous infusion of normal saline is the treatment
                            of choice for restoration of blood pressure.</paragraph><paragraph>While captopril may be removed from the adult circulation by
                            hemodialysis, there is inadequate data concerning the effectiveness of
                            hemodialysis for removing it from the circulation of neonates or
                            children. Peritoneal dialysis is not effective for removing captopril;
                            there is no information concerning exchange transfusion for removing
                            captopril from the general circulation.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="S8EF4CB1E-A155-4A7C-9341-2F9DD5DE6521">
<id root="AB3AC0AF-A2E1-B2B4-305C-BED81762ECD9" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE &amp; ADMINISTRATION" />
<title mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<text><paragraph>Captopril should be taken one hour before meals. Dosage must be
                            individualized.</paragraph></text>
<effectiveTime value="20060328" />
<component>
<section ID="SFE829FA3-C236-418F-BB53-48BDCB2A5BCC">
<id root="65C253DB-3BAD-9C11-C54C-8F4E675117F8" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Hypertension &#8211;</title>
<text><paragraph>Initiation of therapy requires consideration of recent
                                    antihypertensive drug treatment, the extent of blood pressure
                                    elevation, salt restriction, and other clinical circumstances.
                                    If possible, discontinue the patient&#8217;s previous
                                    antihypertensive drug regimen for one week before starting
                                    captopril.</paragraph><paragraph>The initial dose of captopril is 25 mg bid or tid. If
                                    satisfactory reduction of blood pressure has not been achieved
                                    after one or two weeks, the dose may be increased to 50 mg bid
                                    or tid. Concomitant sodium restriction may be beneficial when
                                    captopril is used alone. </paragraph><paragraph>The dose of captopril in hypertension usually does not                        exceed 50 mg tid. Therefore, if the blood pressure has not been
                                    satisfactorily controlled after one to two weeks at this dose,
                                    (and the patient is not already receiving a diuretic), a modest
                                    dose of a thiazide-type diuretic (e.g., hydrochlorothiazide, 25
                                    mg daily), should be added. The diuretic dose may be increased                                 at one- to two-week intervals until its highest usual
                                    antihypertensive dose is reached.</paragraph><paragraph>If captopril is being started in a patient already
                                    receiving a diuretic, captopril therapy should be initiated
                                    under close medical supervision (see <linkHtml href="#S2D1A1BB6-E269-4520-8693-E83DCF365182">WARNINGS</linkHtml> and&#160;<linkHtml href="#S8B1831E5-B0BD-49C5-AF9F-B4F6E1FF7AB6">PRECAUTIONS
                                        [Drug Interactions]</linkHtml> regarding hypotension), with
                                    dosage and titration of captopril as noted above.</paragraph><paragraph>If further blood pressure reduction is required, the dose
                                    of captopril may be increased to 100 mg bid or tid and then, if
                                    necessary, to 150 mg bid or tid (while continuing the diuretic).
                                    The usual dose range is 25 to 150 mg bid or tid. A Maximum daily
                                    dose of 450 mg captopril should not be exceeded.</paragraph><paragraph>For patients with severe hypertension (e.g., accelerated
                                    or malignant hypertension), when temporary discontinuation of
                                    current antihypertensive therapy is not practical or desirable,
                                    or when prompt titration to more normotensive blood pressure
                                    levels is indicated, diuretic should be continued but other
                                    current antihypertensive medication stopped and captopril dosage
                                    promptly initiated at 25 mg bid or tid, under close medical
                                    supervision.</paragraph><paragraph>When necessitated by the patient&#8217;s clinical                     condition, the daily dose of captopril may be increased every 24
                                    hours or less under continuous medical supervision until a
                                    satisfactory blood pressure response is obtained or the maximum
                                    dose of captopril is reached. In this regimen, addition of a
                                    more potent diuretic, e.g., furosemide, may also be indicated. </paragraph><paragraph>Beta-blockers may also be used in conjunction with
                                    captopril therapy (see <linkHtml href="#S8B1831E5-B0BD-49C5-AF9F-B4F6E1FF7AB6">PRECAUTIONS:
                                        Drug Interactions</linkHtml>), but the effects of the two
                                    drugs are less than additive.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SAB9B56A6-2C2C-4655-A59B-C73A50AC1001">
<id root="AA27F1F8-0110-C264-C625-76DB557B7088" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Heart Failure &#8211;</title>
<text><paragraph>Initiation of therapy requires consideration of recent
                                    diuretic therapy and the possibility of severe salt/volume
                                    depletion. In patients with either normal or low blood pressure,
                                    who have been vigorously treated with diuretics and who may be
                                    hyponatremic and/or hypovolemic, a starting dose of 6.25 or 12.5
                                    mg tid may minimize the magnitude or duration of the hypotensive
                                    effect (see <linkHtml href="#S75C0FC90-42F3-438F-8101-526AA40EB6C2">WARNINGS:
                                        Hypotension</linkHtml>); for these patients, titration to
                                    the usual daily dosage can then occur within the next several
                                    days.</paragraph><paragraph>For most patients the usual initial daily dosage is 25 mg
                                    tid. After a dose of 50 mg tid is reached, further increases in
                                    dosage should be delayed, where possible, for at least two weeks
                                    to determine if a satisfactory response occurs. Most patients
                                    studied have had a satisfactory clinical improvement at 50 or
                                    100 mg tid. A maximum daily dose of 450 mg of captopril should
                                    not be exceeded.</paragraph><paragraph>Captopril should generally be used in conjunction with a
                                    diuretic and digitalis. Captopril therapy must be initiated
                                    under very close medical supervision.</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
<component>
<section ID="SDB4B452D-FA8A-484B-B883-8A1AAD9C22E1">
<id root="1E8B1F28-B39D-E065-14B5-4E631190C591" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED" />
<title mediaType="text/x-hl7-title+xml">Dosage Adjustment in Renal Impairment</title>
<text><paragraph>Because captopril is excreted primarily by the kidneys,
                                    excretion rates are reduced in patients with impaired renal                           function. These patients will take longer to reach steady-state
                                    captopril levels and will reach higher steady-state levels for a
                                    given daily dose than patients with normal renal function.
                                    Therefore, these patients may respond to smaller or less          frequent doses.</paragraph><paragraph>Accordingly, for patients with significant renal
                                    impairment, initial daily dosage of captopril should be reduced,
                                    and smaller increments utilized for titration, which should be
                                    quite slow (one- to two-week intervals). After the desired
                                    therapeutic effect has been achieved, the dose should be slowly
                                    back-titrated to determine the minimal effective dose. When
                                    concomitant diuretic therapy is required, a loop diuretic (e.g.,
                                    furosemide), rather than a thiazide diuretic, is preferred in
                                    patients with severe renal impairment. (See&#160;<linkHtml href="#S16E9CAB3-D8D8-402A-8569-806B2DEBA881">WARNINGS:
                                        Anaphylactoid Reactions During Membrane
                                    Exposure</linkHtml>&#160;and <linkHtml href="#S50F24D2D-3F9A-4C5C-8CD7-7EF4298E2514">PRECAUTIONS:
                                        Hemodialysis</linkHtml>.)</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
</section>
</component>
<component>
<section ID="SEE56D029-C829-4EE5-AF7C-DC3B18850F48">
<id root="2E509B84-9083-847B-4904-F52E021C20E9" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED" />
<title mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text><paragraph>Captopril Tablets, USP are supplied as follows:</paragraph><paragraph>12.5 mg &#8211; white, round biconvex tablets: one face
                            embossed with Endo and partially scored, the other embossed with
                            721.<br />&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bottles
                            of 100</paragraph><paragraph>25 mg &#8211; white, round, biconvex tablets; one face
                            embossed with Endo and 722, the other plain and quadrisect
                            scored.<br />&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bottles
                            of 100</paragraph><paragraph>50 mg &#8211; white, round, biconvex tablet; one face
                            embossed with Endo and 724, the other plain and
                            scored.<br />&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bottles
                            of 100</paragraph><paragraph>100 mg &#8211; white, round, biconvex tablets; one face
                            embossed with Endo and 727, the other plain and
                            scored.<br />&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bottles
                            of 100</paragraph><paragraph>All captopril tablets are white and may exhibit a slight
                            sulfurous odor. Store at controlled room temperature,
                            15&#176;-30&#176;C (59&#176;-86&#176;F). Dispense in a
                            tight container (protect from moisture).</paragraph><paragraph><content styleCode="bold">Caution:</content> Federal (USA) law
                            prohibits dispensing without prescription.</paragraph><paragraph>Manufactured by:<br />DuPont Pharma<br />Wilmington, Delaware 19880 </paragraph><paragraph>6429/February, 1995</paragraph></text>
<effectiveTime value="20060328" />
</section>
</component>
</structuredBody>
</component>
</document>
